Fermenta Biotech: 74th AGM Presentation Highlights Growth, Innovation, and Financial Strength
Fermenta Biotech reported record FY26 revenue of ₹548 crore, up 14% YoY, with core EBITDA at ₹120 crore and PAT of ₹70 crore. The company secured a plant-source Vitamin D3 patent and an EDQM CEP for D3 100 SD. A ₹110 crore capex is approved for new capacity. Free cash flow tripled to ₹62 crore.
The announcement covers key financial results, significant capital expenditure plans, strategic innovations like patent approvals for key products, and strong financial performance metrics, which are material to investors.
The announcement highlights record revenue, significant EBITDA growth, patent approvals, new capacity investment, and strong free cash flow generation, all indicating positive business performance and future outlook.
Fermenta Biotech Limited has presented its materials for the 74th Annual General Meeting (AGM), detailing a year of "operating momentum, renewed strategic conviction, and capital commitment" for FY26.
The company reported a record consolidated revenue of ₹548 crore for FY26, a 14% increase from ₹481 crore in FY25, with core EBITDA ex-real estate growing by 44% to ₹120 crore. Profit After Tax (PAT) stood at ₹70 crore, compared to a high FY25 base that included ₹45 crore of one-off real estate income. Fermenta highlighted ten consecutive quarters of positive results across all operating businesses.
Key innovations include the granting of a plant-source Vitamin D3 process patent and an EDQM CEP for D3 100 SD. The board has also approved a ₹110 crore capital expenditure for new capacity at Dahej, focusing on plant-source Vitamin D3, Calcifediol, and biocatalysis enzymes.
Financially, the company achieved a revenue of ₹548 crore in FY26, with EBITDA at ₹122 crore and PAT at ₹70 crore. Operating cash flow more than doubled to ₹93 crore, and free cash flow tripled to ₹62 crore, supporting stepped-up capex. The company maintained a strong balance sheet with total debt at ₹109 crore and equity at ₹401 crore.
Fermenta emphasized its leadership position as one of the world's top 3 Vitamin D3 manufacturers, serving over 400 customers in more than 60 countries. The strategy focuses on accelerating growth, diversifying the portfolio, and strengthening global leadership through innovation in chemistry, manufacturing excellence, and a risk-aware growth strategy.
What to do with a filing like this
Fermenta Biotech Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fermenta Biotech Limited. Read the original for the full detail.